In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.
May 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
In the phase 3 PEAK trial, bezuclastinib plus sunitinib significantly improved median progression-free survival vs sunitinib alone in patients with advanced gastrointestinal stromal tumors after prior...
How can primary care clinicians diagnose and manage IBS-C and chronic idiopathic constipation? Joel J. Heidelbaugh, MD, outlines evidence-based treatment options, alarm features, and when to refer to...
A double-blind, placebo-controlled cross-over trial published in BMC Gastroenterology evaluated whether 12 g/day of chicory inulin improves bowel habits, patient-reported outcomes, and gut microbiota...
In a randomized controlled trial of adults with Rome IV irritable bowel syndrome without constipation, investigators found that a Mediterranean-style low-FODMAP diet produced greater symptom improvement,...
A randomized, double-blind trial evaluated whether 4 commonly used nutritional supplements could improve symptoms or microbiota-related outcomes in adults with irritable bowel syndrome.
Recurrent Clostridioides difficile infection remains a significant clinical challenge, with high rates of relapse and limited access to traditional FMT. Newly FDA-approved live biotherapeutic products offer...
A new study finds that oral fecal microbiota transplantation (FMT) capsules combined with partial enteral nutrition are as effective as immunosuppressants in treating pediatric Crohn disease. The treatment...
For patients with type 2 diabetes and established cardiovascular or kidney disease, daily oral semaglutide significantly lowered the risk of major adverse cardiovascular events during a median of 49.5...
